Everything is done for a reason. There is enough data to narrow down commercial opportunities without simply going off and doing preclinicals on random things.
I would imagine that the thought process is as follows:
1. AML (Bisantrene+Decitabine) -> P2 results -> licensing.
2. Solid tumour (all comers) Bisantrene+Decitabine drug supply -> Investigator sponsor -> licensing.
3. Kyprolis+Bisantrene (CPACS) -> Drug supply -> investigator sponsor-> licensing
4. CPACS (Dox+Bisantrene) all comers - Amgen?
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-43
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
0.120(6.80%) |
Mkt cap ! $321.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.93 | $1.78 | $563.4K | 302.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 108 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 4926 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |